Oral tocolysis with magnesium chloride: A randomized controlled prospective clinical trial

Jean M. Ricci, Seemanthini Hariharan, Andrew Helfgott, Karel Reed, Mary Jo O'Sullivan

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

A prospective randomized clinical trial was conducted to assess the efficacy and safety of enteric-coated magnesium chloride (SLOW MAG) as an oral tocolytic agent. Seventy-five patients between 24 and 34 weeks' gestation who were treated with intravenous magnesium sulfate for a first episode of preterm labor were enrolled. After a 12-hour contraction-free period on intravenous therapy, patients were randomized by sealed envelope to one of three groups: group 1, SLOW MAG (535 mg every 4 hours); group 2, oral ritodrine (20 mg every 4 hours); or group 3, no therapy (control). Patients receiving oral therapy were treated until delivery or completion of 36 weeks' gestation. No difference was found between groups with respect to time gained with the use of oral therapy or number completing 36 weeks' gestation. Therapy with enteric-coated magnesium chloride was associated with significantly fewer side effects (20%) as compared with ritodrine (48%) (p < 0.01). Our results suggest that compared with ritodrine, enteric-coated magnesium chloride is as effective in prolonging pregnancy and preventing recurrent preterm labor. However, neither enteric-coated magnesium chloride nor ritodrine appeared to be any more effective in the prevention of preterm delivery than observation alone.

Original languageEnglish
Pages (from-to)603-610
Number of pages8
JournalAmerican Journal of Obstetrics and Gynecology
Volume165
Issue number3
DOIs
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Tocolysis
Magnesium Chloride
Ritodrine
Randomized Controlled Trials
Pregnancy
Premature Obstetric Labor
Tocolytic Agents
Therapeutics
Magnesium Sulfate
Observation
Safety

Keywords

  • magnesium chloride
  • oral tocolysis
  • Preterm labor
  • ritodrine

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Oral tocolysis with magnesium chloride : A randomized controlled prospective clinical trial. / Ricci, Jean M.; Hariharan, Seemanthini; Helfgott, Andrew; Reed, Karel; O'Sullivan, Mary Jo.

In: American Journal of Obstetrics and Gynecology, Vol. 165, No. 3, 01.01.1991, p. 603-610.

Research output: Contribution to journalArticle

Ricci, Jean M. ; Hariharan, Seemanthini ; Helfgott, Andrew ; Reed, Karel ; O'Sullivan, Mary Jo. / Oral tocolysis with magnesium chloride : A randomized controlled prospective clinical trial. In: American Journal of Obstetrics and Gynecology. 1991 ; Vol. 165, No. 3. pp. 603-610.
@article{736bd723665441bb9438d06d75c75694,
title = "Oral tocolysis with magnesium chloride: A randomized controlled prospective clinical trial",
abstract = "A prospective randomized clinical trial was conducted to assess the efficacy and safety of enteric-coated magnesium chloride (SLOW MAG) as an oral tocolytic agent. Seventy-five patients between 24 and 34 weeks' gestation who were treated with intravenous magnesium sulfate for a first episode of preterm labor were enrolled. After a 12-hour contraction-free period on intravenous therapy, patients were randomized by sealed envelope to one of three groups: group 1, SLOW MAG (535 mg every 4 hours); group 2, oral ritodrine (20 mg every 4 hours); or group 3, no therapy (control). Patients receiving oral therapy were treated until delivery or completion of 36 weeks' gestation. No difference was found between groups with respect to time gained with the use of oral therapy or number completing 36 weeks' gestation. Therapy with enteric-coated magnesium chloride was associated with significantly fewer side effects (20{\%}) as compared with ritodrine (48{\%}) (p < 0.01). Our results suggest that compared with ritodrine, enteric-coated magnesium chloride is as effective in prolonging pregnancy and preventing recurrent preterm labor. However, neither enteric-coated magnesium chloride nor ritodrine appeared to be any more effective in the prevention of preterm delivery than observation alone.",
keywords = "magnesium chloride, oral tocolysis, Preterm labor, ritodrine",
author = "Ricci, {Jean M.} and Seemanthini Hariharan and Andrew Helfgott and Karel Reed and O'Sullivan, {Mary Jo}",
year = "1991",
month = "1",
day = "1",
doi = "10.1016/0002-9378(91)90293-Z",
language = "English",
volume = "165",
pages = "603--610",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Oral tocolysis with magnesium chloride

T2 - A randomized controlled prospective clinical trial

AU - Ricci, Jean M.

AU - Hariharan, Seemanthini

AU - Helfgott, Andrew

AU - Reed, Karel

AU - O'Sullivan, Mary Jo

PY - 1991/1/1

Y1 - 1991/1/1

N2 - A prospective randomized clinical trial was conducted to assess the efficacy and safety of enteric-coated magnesium chloride (SLOW MAG) as an oral tocolytic agent. Seventy-five patients between 24 and 34 weeks' gestation who were treated with intravenous magnesium sulfate for a first episode of preterm labor were enrolled. After a 12-hour contraction-free period on intravenous therapy, patients were randomized by sealed envelope to one of three groups: group 1, SLOW MAG (535 mg every 4 hours); group 2, oral ritodrine (20 mg every 4 hours); or group 3, no therapy (control). Patients receiving oral therapy were treated until delivery or completion of 36 weeks' gestation. No difference was found between groups with respect to time gained with the use of oral therapy or number completing 36 weeks' gestation. Therapy with enteric-coated magnesium chloride was associated with significantly fewer side effects (20%) as compared with ritodrine (48%) (p < 0.01). Our results suggest that compared with ritodrine, enteric-coated magnesium chloride is as effective in prolonging pregnancy and preventing recurrent preterm labor. However, neither enteric-coated magnesium chloride nor ritodrine appeared to be any more effective in the prevention of preterm delivery than observation alone.

AB - A prospective randomized clinical trial was conducted to assess the efficacy and safety of enteric-coated magnesium chloride (SLOW MAG) as an oral tocolytic agent. Seventy-five patients between 24 and 34 weeks' gestation who were treated with intravenous magnesium sulfate for a first episode of preterm labor were enrolled. After a 12-hour contraction-free period on intravenous therapy, patients were randomized by sealed envelope to one of three groups: group 1, SLOW MAG (535 mg every 4 hours); group 2, oral ritodrine (20 mg every 4 hours); or group 3, no therapy (control). Patients receiving oral therapy were treated until delivery or completion of 36 weeks' gestation. No difference was found between groups with respect to time gained with the use of oral therapy or number completing 36 weeks' gestation. Therapy with enteric-coated magnesium chloride was associated with significantly fewer side effects (20%) as compared with ritodrine (48%) (p < 0.01). Our results suggest that compared with ritodrine, enteric-coated magnesium chloride is as effective in prolonging pregnancy and preventing recurrent preterm labor. However, neither enteric-coated magnesium chloride nor ritodrine appeared to be any more effective in the prevention of preterm delivery than observation alone.

KW - magnesium chloride

KW - oral tocolysis

KW - Preterm labor

KW - ritodrine

UR - http://www.scopus.com/inward/record.url?scp=0025737483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025737483&partnerID=8YFLogxK

U2 - 10.1016/0002-9378(91)90293-Z

DO - 10.1016/0002-9378(91)90293-Z

M3 - Article

C2 - 1892185

AN - SCOPUS:0025737483

VL - 165

SP - 603

EP - 610

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3

ER -